- Strong Financial Outlook: Analysts forecast increased earnings per share $2.85 and revenue $25.02 billion for Q2 2026, continuing a trend of outperforming expectations.
- Robust Stock Performance: Johnson & Johnson stock has risen over 20% year-to-date, reaching a new all-time high of $269 per share, with analysts raising price targets.
- Solid Valuation & Health: The company maintains a trailing P/E ratio of 29.28 and a healthy debt-to-equity ratio of 0.68, reflecting its defensive qualities and strong balance sheet.
Johnson & Johnson (NYSE: JNJ) is a global healthcare company operating in pharmaceuticals, medical devices, and consumer health. The company is known for its defensive qualities, meaning its business tends to remain stable even during economic downturns. This stability is supported by consistent earnings growth and a strong balance sheet, though it faces challenges from patent expirations.
Johnson & Johnson is set to release its second-quarter earnings report on July 15, 2026, before the market opens. Wall Street analysts are forecasting an earnings per share (EPS) of $2.85. This figure represents an expected increase from the $2.77 per share reported in the same quarter of the previous year, signaling anticipated profit growth.
The consensus revenue estimate for the quarter is approximately $25.02 billion. This projection is higher than the $23.74 billion in revenue Johnson & Johnson generated a year ago. Johnson & Johnson has a strong history of outperforming expectations, having beaten analyst revenue estimates for the last eight consecutive quarters.
Ahead of the report, Johnson & Johnson’s stock has performed strongly, rising over 20% year-to-date and reaching a new all-time high of $269 per share, as highlighted by Zacks. Reflecting this positive sentiment, analysts at TD Cowen raised their price target to $300, while Freedom Capital Markets increased its price target to $287.
From a valuation standpoint, Johnson & Johnson has a trailing price-to-earnings (P/E) ratio of 29.28. This metric suggests investors are paying $29.28 for every dollar of the company’s past earnings. The company’s financial health is also reflected in its debt-to-equity ratio of 0.68, indicating it has less debt than shareholder equity.
